Concepedia

Publication | Closed Access

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

DOI

337

Citations

13

References

2013

Year

X. Pivot, Gilles Romieu, Marc Debled, Jean‐Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, P. Fumoleau, Daniel Serin,
The Lancet Oncology

References

YearCitations

Page 1